Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1920 ARTÍCULOS , VIENDO DEL 1606 AL 1620

Gene therapy: an alternative to treat Alzheimer's disease

Doshi V, Joshi G, Sharma S, Choudhary D.

Naunyn Schmiedebergs Arch Pharmacol. 2024 Jun;397(6):3675-3693. doi: 10.1007/s00210-023-02873-z. Epub 2023 Dec 11.

Effectiveness of epigallocatechin gallate nanoparticles on the in-vivo treatment of Alzheimer's disease in a rat/mouse model: a systematic review

Khalifa MKA, Abdel-Sattar SA, Amin OM, Kohaf NA, Zaky HS, Abd El-Fattah MA, Mohammed KHA, Badawi NM, Mansoor I, Eassa HA.

Daru. 2024 Jun;32(1):319-337. doi: 10.1007/s40199-023-00494-8. Epub 2023 Dec 11.

Unravelling the in vitro and in vivo potential of selenium nanoparticles in Alzheimer's disease: A bioanalytical review

Vicente-Zurdo D, Rosales-Conrado N, León-González ME.

Talanta. 2024 Mar 1;269:125519. doi: 10.1016/j.talanta.2023.125519. Epub 2023 Dec 7.

Role of sleep in neurodegeneration: the consensus report of the 5th Think Tank World Sleep Forum

Ferini-Strambi L, Liguori C, Lucey BP, Mander BA, Spira AP, Videnovic A, Baumann C, Franco O, Fernandes M, Gnarra O, Krack P, Manconi M, Noain D, Saxena S, Kallweit U, Randerath W, Trenkwalder C, Rosenzweig I, Iranzo A, Bradicich M, Bassetti C.

Neurol Sci. 2024 Feb;45(2):749-767. doi: 10.1007/s10072-023-07232-7. Epub 2023 Dec 13.

Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease

Park J, Simpson C, Patel K.

Ann Pharmacother. 2024 Oct;58(10):1045-1053. doi: 10.1177/10600280231218253. Epub 2023 Dec 14.

Lecanemab: More Questions Than Answers!

Kaur U, Reddy J, Tiwari A, Chakrabarti S, Chakrabarti SS.

Clin Drug Investig. 2024 Jan;44(1):1-10. doi: 10.1007/s40261-023-01331-1. Epub 2023 Dec 14.

Machine learning in Alzheimer's disease drug discovery and target identification

Geng C, Wang Z, Tang Y.

Ageing Res Rev. 2024 Jan;93:102172. doi: 10.1016/j.arr.2023.102172. Epub 2023 Dec 16.

Comparison of Neuroinflammation Induced by Hyperphosphorylated Tau Protein Versus Ab42 in Alzheimer's Disease

Rice M, Nuovo GJ, Sawant D, Mishra A, Tili E.

Mol Neurobiol. 2024 Jul;61(7):4589-4601. doi: 10.1007/s12035-023-03822-w. Epub 2023 Dec 18.

Complicated Role of Post-translational Modification and Protease-Cleaved Fragments of Tau in Alzheimer's Disease and Other Tauopathies

Yang J, Shen N, Shen J, Yang Y, Li HL.

Mol Neurobiol. 2024 Jul;61(7):4712-4731. doi: 10.1007/s12035-023-03867-x. Epub 2023 Dec 20.

Audiovisual gamma stimulation for the treatment of neurodegeneration

Blanco-Duque C, Chan D, Kahn MC, Murdock MH, Tsai LH.

J Intern Med. 2024 Feb;295(2):146-170. doi: 10.1111/joim.13755. Epub 2023 Dec 19.

Tau and Alzheimer's disease: Past, present and future

Iqbal K.

Cytoskeleton (Hoboken). 2024 Jan;81(1):116-121. doi: 10.1002/cm.21822. Epub 2023 Dec 21.

Curcumin hybrid molecules for the treatment of Alzheimer's disease: Structure and pharmacological activities

Zang WB, Wei HL, Zhang WW, Ma W, Li J, Yao Y.

Eur J Med Chem. 2024 Feb 5;265:116070. doi: 10.1016/j.ejmech.2023.116070. Epub 2023 Dec 18.

Caspases in Alzheimer's Disease: Mechanism of Activation, Role, and Potential Treatment

Wójcik P, Jastrzębski MK, Zięba A, Matosiuk D, Kaczor AA.

Mol Neurobiol. 2024 Jul;61(7):4834-4853. doi: 10.1007/s12035-023-03847-1. Epub 2023 Dec 23.

Bridging neurotrophic factors and bioactive peptides to Alzheimer's disease

Wei M, Wu T, Chen N.

Ageing Res Rev. 2024 Feb;94:102177. doi: 10.1016/j.arr.2023.102177. Epub 2023 Dec 22.

Targeting glycogen synthase kinase-3β for Alzheimer's disease: Recent advances and future Prospects

Cheng Z, Han T, Yao J, Wang K, Dong X, Yu F, Huang H, Han M, Liao Q, He S, Lyu W, Li Q.

Eur J Med Chem. 2024 Feb 5;265:116065. doi: 10.1016/j.ejmech.2023.116065. Epub 2023 Dec 20.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias